Loading
CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network. Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilisation of kinetochore fibres of the mitotic spindle by acting as inter-microtubule bridge.
Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.84, affected pathway 0.94, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Hepatocellular Carcinoma, Upper Tract Urothelial Carcinoma.
In plain words · CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network.
No product in this corpus aims at CLTC yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1991. Earliest sequence paper UniProt cites for the protein: Dodge G.R. et al, Genomics, 1991, "Human clathrin heavy chain (CLTC): partial molecular cloning, expression, and mapping of the gene to human chromosome 17q11-qter". Source.
Sources: HGNC HGNC:2092 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q00610 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000141367 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, melanoma 0.51, non-Hodgkin lymphoma 0.53, breast cancer 0.55, lung cancer 0.53 (GraphQL API, CC0)); IntOGen CLTC (driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network. Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilisation of kinetochore fibres of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fibre tension. Plays a role in early autophagosome formation. Interaction with DNAJC6 mediates the recruitment of HSPA8 to the clathrin lattice and creates local destabilisation of the lattice promoting uncoating. Location: Cytoplasmic vesicle membrane; Membrane, coated pit; Melanosome; Cytoplasm, cytoskeleton, spindle (UniProt). Locus 17q23.1 (HGNC).
Query for this target: (TITLE:"CLTC" OR ABSTRACT:"CLTC" OR TITLE:"clathrin heavy chain" OR ABSTRACT:"clathrin heavy chain" OR TITLE:"Clathrin heavy chain 1" OR ABSTRACT:"Clathrin heavy chain 1" OR TITLE:"Hc" OR ABSTRACT:"Hc" OR TITLE:"CLTCL2" OR ABSTRACT:"CLTCL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CLTC, not a curated reading list.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Bladder & urothelial cancer, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Lung cancer (all types).
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Breast cancer (all types).
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.